Creo Medical Group PLC (LON:CREO – Get Rating) shares were up 4.2% on Wednesday . The stock traded as high as GBX 25 ($0.31) and last traded at GBX 24.75 ($0.31). Approximately 291,266 shares changed hands during trading, a decline of 58% from the average daily volume of 695,300 shares. The stock had previously closed […]
Creo Medical Limited (LON:CREO – Get Rating) insider Charles Spicer acquired 15,435 shares of the firm’s stock in a transaction on Thursday, May 26th. The shares were acquired at an average price of GBX 97 ($1.22) per share, with a total value of £14,971.95 ($18,839.75). Shares of LON CREO opened at GBX 97.50 ($1.23) on […]
Creo Medical Limited (LON:CREO – Get Rating)’s stock price traded down 4% on Tuesday . The stock traded as low as GBX 118.55 ($1.54) and last traded at GBX 120 ($1.56). 33,243 shares traded hands during mid-day trading, a decline of 78% from the average session volume of 149,919 shares. The stock had previously closed […]
19 May 2021 | 09:55am
StockMarketWire.com - Medical device company Creo Medical upgraded its outlook on annual revenue after first-quarter results topped management s expectations.
Revenue performance for the year ending 31 December 2021 would be at least 10% ahead of current market expectations of £20.1m, the company said. The current year has started well, with trading in the three months ended 31 March 2021 ahead of management s expectations. There has been an increase in commercial activity from Creo s core products together with strong contributions from Albyn Medical and Boucart Medical, which were acquired during 2020, it added. The strengthening of the company s commercial team, both organically under the direction of David Woods, and through acquisitions made by the Group during 2020, has been highly successful.
17 February 2021 | 08:11am
StockMarketWire.com - Medical device company Creo Medical said annual performance was marginally ahead of management s expectation amid ongoing commerical progress thanks to a boost from acquisitions.
For the year ended 31 December 2020, revenue jumped to over £9 million from £0.01 million a year earlier, with net cash position in excess of £45 million.
The acquisitions of Albyn Medical S.L. and Boucart Medical SRL provided the company with a direct sales presence in Europe to facilitate the roll-out of its CE marked advanced energy devices, and strengthen Creo s EU and UK commercial teams, the company said. In 2021, the immediate focus for the company is to deliver clinical outcomes for all devices, Creo said.